✦ LIBER ✦

A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK

✍ Scribed by A. Ratcliffe; C. Poole; D. Miles

Book ID: 117657589
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 165 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)80043-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multinational phase II study of Navelb

A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

✍ M Untch; S Kahlert; L Petruzelka; M Martin; V Guillem-Porta; M Gil; P Kellokumpu 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 182 KB

A cost-benefit analysis of bevacizumab i

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

✍ Alberto J. Montero; Kiran Avancha; Stefan Glück; Gilberto Lopes 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 177 KB

Results of a phase II study of liposomal

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

✍ J Baselga; M.A Climent; A Lluch; J Hornedo; P Gascon; A.T Sanchez; V Guillem; H 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 173 KB

446 PUBLICATION A phase II trial of tras

446 PUBLICATION A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

PCN69 COST-EFFECTIVENESS OF ADDING CAPEC

PCN69 COST-EFFECTIVENESS OF ADDING CAPECITABINE TO TRASTUZUMAB AND DOCETAXEL AS FIRST LINE THERAPY FOR PATIENTS WITH HER-2-POSITIVE METASTATIC BREAST CANCER (HER2+MBC)—RESULTS FROM SPAIN, FRANCE AND ITALY

✍ K Hieke; P Ducournau; F de Reydet de Vulpillières 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB